The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug distribution and assess the tumor response to prolonged continuous CED of Topotecan.
Convection Enhanced Delivery is a novel method of drug delivery that allows administration of a drug directly to the brain. In CED, a drug pump is placed under the skin in the chest or abdominal region. The pump is connected to a catheter that is tunneled underneath the skin to the brain. The tip of the catheter then infuses Topotecan directly onto the brain tumor. There will be a total of four treatment infusions over the course of 23-29 days, with a 5-7-day rest period between each infusion. Throughout this period, patients' health will be monitored through imaging, blood draws, and regular exams. At the end of the treatment period, the pump will be removed, followed by resection of the tumor. Patients will be followed for the duration of their lives.
This is the investigator's second clinical trial studying CED of TPT in recurrent glioma. In the prior Phase 1b trial, chronic pulsatile CED safely and effectively delivered Topotecan to patients with IDH mutant recurrent Glioblastoma (WHO grade 4).

Start Date04 Oct 2025

Sponsor / Collaborator

Columbia University

NCT06930755

/ Not yet recruitingPhase 1

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer

This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.

Start Date28 Jun 2025

Sponsor / Collaborator

Nerviano Medical Sciences S.r.l

NCT06942039

/ Not yet recruitingEarly Phase 1

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.

Start Date01 Jun 2025

Sponsor / Collaborator

C17 Council

100 Clinical Results associated with Topotecan Hydrochloride

100 Translational Medicine associated with Topotecan Hydrochloride

100 Patents (Medical) associated with Topotecan Hydrochloride

5,459

Literatures (Medical) associated with Topotecan Hydrochloride

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous analysis of various anticancer drugs by supercritical fluid chromatography-mass spectrometry. Part I: Optimization of chromatographic separation

Article

Author: Guillarme, Davy ; Rudaz, Serge ; Fleury-Souverain, Sandrine ; Nguyen, Nathalie ; Bonnabry, Pascal

This work presents a generic SFC-MS method for the simultaneous analysis of 22 anticancer drugs (fluorouracil, busulfan, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, gemcitabine, idarubicin, ifosfamide, irinotecan, methotrexate, paclitaxel, pemetrexed, raltitrexed, topotecan, treosulfan, vinblastine, vincristine). The separation conditions were optimized by screening nine stationary phases (2-picolylamine, bare hybrid silica, 2-ethylpyridine, fluoro-phenyl, octadecyl, diethylamine, diol, 1-aminoanthracene, zwitterionic modification), evaluating additives effects (2-5 % water, 20-50 mM ammonium formate, 0-1 mM ammonium fluoride), and adjusting the organic modifier composition (methanol, ethanol, isopropanol, acetonitrile). The optimized SFC-MS method successfully analyzed 22 anticancer drugs, along with 5 additional challenging compounds (azacitidine, mitomycin, cisplatin, oxaliplatin, carboplatin), in 12 min, using a diol column (100 × 3 mm, 1.7 µm) and a gradient of 2-100 % methanol containing 2 % water and 50 mM ammonium formate. To overcome overpressure generated by high organic solvent content, a backpressure gradient (110-150 bar) and a flow rate gradient (0.6-1.5 mL/min) were applied. The diol column was selected as the most promising based on five predefined chromatographic criteria. Additives with 5 % water or ammonium fluoride were excluded due to overpressure and signal loss, respectively. Increasing ammonium formate concentration improved peak symmetry by 29 %. For the organic modifier, pure methanol was chosen since ternary mixtures led to system overpressure without improving separation. Comparison with the LC-MS method using real samples confirmed the potential applicability of the SFC method, as the same trace compounds were detected with comparable concentrations. Sensitivity optimization and method validation will be discussed separately in a later paper.

01 Jul 2025·PEDIATRIC BLOOD & CANCER

Identification of Anticancer Drugs Associated With Cancer Therapy‐Related Cardiac Dysfunction in Pediatrics—Analysis of the WHO Pharmacovigilance Database

Article

Author: Rouger, Jérémie ; Dolladille, Charles ; Labombarda, Fabien ; Chrétien, Basile ; Alexandre, Joachim ; Legallois, Damien

ABSTRACT:

Aims:

Cardiovascular toxicities associated with anticancer drugs constitute a significant concern for pediatric patients undergoing cancer treatment. Comprehensive data on the burden of cancer therapy‐related cardiac dysfunction (CTRCD) are lacking, particularly for this high‐risk population susceptible to develop myocardial toxicity. By analyzing VigiBase, the World Health Organization's individual case safety report database, we sought to determine anticancer drugs associated with CTRCD in pediatric patients.

Methods and Results:

To evaluate the association between 249 anticancer drugs labeled by the FDA or EMA and CTRCD reporting, we performed a disproportionality analysis, calculating multivariable adjusted reporting odds ratios (aROR) with their 95% confidence intervals (CI) across four pediatric age classes (0–27 days, 28 days to 23 months, 2–11 years, 12–17 years); ClinicalTrial registration number: NCT05602103. We identified 796 cases of CTRCD associated with at least one anticancer drug in VigiBase. Multivariate analysis across the pediatric age spectrum revealed 16 anticancer drugs significantly associated with CTRCD, of which 10 (63%) are primarily used for hematologic malignancies. Two drugs, a topoisomerase 1 inhibitor (topotecan) and cytotoxic antibiotics (dactinomycin), represented novel associations with CTRCD not previously documented in the literature.

Conclusion:

Within VigiBase, we pinpointed 16 anticancer drugs significantly associated with CTRCD reporting in pediatrics. Our research validated several associations already thoroughly reported in children (such as with anthracyclines), and unveiled novel signals for systemic exposure to topotecan and dactinomycin. The relevance of these findings, especially considering the frequency of co‐administration of agents and the lack of information regarding radiation exposure and chemotherapy dosage, would need to be evaluated in the context of clinical trials that use or have used these agents.

16 May 2025·Recent Patents on Anti-Cancer Drug Discovery

B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance

Article

Author: Cao, Ri-Hui ; Cai, Chao-Yun ; Yang, Dong-Hua ; Wen, Yan ; Zhao, Ruiqiang ; Wang, Jing-Quan ; Lei, Zi-Ning ; Chen, Zhe-Sheng ; Gupta, Pranav

Background::

Multidrug resistance (MDR) in cancer is a major obstacle to achieving success in clinical chemotherapy. It has been observed that overexpression of ATP-Binding Cassette (ABC) transporters plays a crucial role in MDR.

Objective::

This study aimed to find an effective resistance-reversed agent of ABC transporter. A series of new β-carboline derivatives have been synthesized and are being applied in various invention patents. One of these is B-9-8, a novel harman dimer, which was synthesized to conduct a series of experiments.

Methods::

In this study, we investigated whether B-9-8 could reverse ABCG2-mediated drug resistance by using MTT assay, [3H]-mitoxantrone accumulation/efflux assay, western blot analysis, immunofluorescence analysis, ATPase assay, and molecular modeling assay.

Results::

The results showed that B-9-8 could significantly increase the sensitivity of mitoxantrone, SN-38, and topotecan and effectively overcame drug resistance at non-toxic concentrations in ABCG2-overexpressing cells. Further studies showed that B-9-8 increased the intracellular accumulation of [3H]-mitoxantrone by suppressing the efflux function of ABCG2 in ABCG2-overexpressing cells. B-9-8 could down-regulate the ABCG2 protein expression but did not change the subcellular localization of ABCG2. ATPase analysis indicated that B-9-8 inhibited the ATPase activity of ABCG2 in a concentration-dependent manner. In the molecular docking analysis, B-9-8 demonstrated a strong interaction with the human ABCG2 transporter protein.

Conclusion::

Our findings indicated that B-9-8 could reverse ABCG2-mediated MDR as a potential and reversible modulator in combination with conventional chemotherapeutic drugs.

189

News (Medical) associated with Topotecan Hydrochloride

22 May 2025

·www.fiercepharma.com

ASCO: Roche, Jazz's Zepzelca small cell lung cancer win leaves room for improvement

For Roche, adding Zepzelca as a combination partner could help shore up Tecentriq in first-line ES-SCLC in its competition with AstraZeneca’s Imfinzi. Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders.Adding Zepzelca on top of Tecentriq as maintenance treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) significantly reduced patients’ risk of death by 27% compared with Tecentriq alone, according to data from the phase 3 IMforte trial.Patients who received the combo lived a median 13.2 months, versus 10.6 for those who got Tecentriq alone. The results will be presented at the 2025 American Society of Clinical Oncology annual meeting.Besides hitting its overall survival goal, IMforte also showed that by taking Zepzelca, patients had a 46% lower risk of cancer progression or death. The median progression-free survival time was 5.4 months for the combo versus 2.1 months in the Tecentriq-alone arm.For Roche, adding Zepzelca as a combination partner could help shore up Tecentriq in first-line ES-SCLC in its competition with AstraZeneca’s Imfinzi. For Jazz, the phase 3 win could move Zepzelca from the post-chemo setting to first-line treatment and maybe also turn the drug’s accelerated approval into a full nod.But as ASCO Chief Medical Officer Julie Gralow, M.D., remarked during a press briefing, there’s still room for improvement.“While this is a next step, progression-free survival is still quite low in both arms, and we need to work on additional ways of advancing this even further,” she said. And a better therapy is desired not just on the efficacy side. The addition of Zepzelca during the maintenance phase more than doubled the rate of treatment-related adverse events to 83.5%, compared with 40% in the control group. The rate of grade 3 or 4 adverse events was also notably higher, at 25.6% for the combo, versus 5.8% for Tecentriq alone. But most adverse events were manageable, which is “one of the reasons that Zepzelca was a really good choice for a maintenance regimen,” Jazz’s R&D head, Rob Iannone, M.D., said in an interview with Fierce Pharma.Adverse events led 6.2% of patients in the experimental arm to discontinue treatment, versus 3.3% in the control arm. Iannone described the rate as “very low.” The Zepzelca arm also saw marginally more frequent treatment-related deaths, at 0.8% versus 0.4%, respectively.For existing first-line ES-SCLC regimens involving Tecentriq or Imfinzi, patients receive chemotherapies only during the induction phase because continued dosing in the maintenance phase turned out to be detrimental due to toxicities, Iannone noted.But once that chemo is taken off, there’s a notable worsening of progression curves. That’s why Jazz and Roche figured patients still need another active therapy that’s better tolerated than traditional chemo that can be given as maintenance treatment, Iannone explained.However, as Gralow pointed out, Zepzelca, as a DNA transcription inhibitor, is still a type of chemotherapy, albeit a safer one.More novel agents are emerging. The DLL3 drug class, led by Amgen’s bispecific Imdelltra, has attracted much enthusiasm—including recently from Roche—for its potential in SCLC. Last year, Amgen launched the phase 3 DeLLphi-305 trial adding Imdelltra to Imfinzi as first-line maintenance treatment of ES-SCLC, with an estimated primary completion date in July 2027.Imdelltra’s future looks promising after Amgen recently reported a positive readout in a phase 3 trial in second-line SCLC. It marked the first overall survival win for a T-cell engager in a solid tumor. At least for now, Zepzelca is the first one to have a positive phase 3 readout in this disease setting, and Iannone argued that the results are practice-changing and serve as a new paradigm for future drugs in the space. Jazz has submitted the IMforte results to the FDA, which has yet to set a target decision date, according to Iannone.IMforte is one of two phase 3 trials that the FDA has agreed could potentially confirm Zepzelca’s clinical benefit after a lower dose of the drug failed to move the needle against chemo in second-line SCLC in the phase 3 Atlantis study. IMforte was sponsored by Roche.The other phase 3 trial that the FDA said could give Zepzelca a traditional approval, Lagoon, finished enrollment in December and could read out topline data in the first quarter of 2026, according to PharmaMar. The three-arm trial evaluates Zepzelca either as monotherapy or in combination with irinotecan against the physician’s choice of topotecan or irinotecan.Jazz in-licensed U.S. rights to Zepzelca from PharmaMar in 2019 by paying $200 million upfront and committing up to $800 million in potential milestones.Jazz has a good track record in licensing cancer drugs. The company’s HER2-targeted bispecific Ziihera, licensed from Zymeworks, recently won FDA approval in HER2-positive biliary tract cancer and is moving toward gastric cancer and breast cancer.After CEO Bruce Cozadd highlighted the company’s continued interest in dealmaking, Jazz agreed to buy Chimerix for $935 million to get hold of dordaviprone, a near-approval small molecule being evaluated by the FDA in recurrent H3 K27M-mutant diffuse glioma.As to Jazz’s future business development plan in oncology, Iannone said: “We are agnostic to modality, again, focused on drugs that will make a meaningful difference for patients, where Jazz really has the capability to develop and commercialize.”

Phase 3Clinical ResultDrug ApprovalAcquisitionASCO

13 Apr 2025

·www.pharmaindustrial-india.com

Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study

Amgen has announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy. "Small cell lung cancer is one of the most aggressive malignancies, with a high unmet need for more effective therapies.1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care," said Jay Bradner, M.D., executive vice president, Research and Development, at Amgen. "We look forward to sharing these results with the scientific community and health authorities as we continue our efforts to bring IMDELLTRA to patients worldwide," added Bradner. The safety profile for IMDELLTRA was consistent with its known profile. Detailed data from DeLLphi-304 will be presented at an upcoming medical congress. DeLLphi-304 is a global Phase 3 randomised controlled open-label clinical trial evaluating the efficacy and safety of IMDELLTRA as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy.2 Patients were randomised to receive either IMDELLTRA or local SOC chemotherapy (topotecan in all countries except Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; and amrubicin in Japan). The primary outcome measure of the trial is OS.

Clinical ResultPhase 3

12 Apr 2025

·pipelinereview.com

Imdelltra® demonstrated superior overall survival in small cell lung cancer

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, CA, USA I April 11, 2025 I Amgen (NASDAQ: AMGN ) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA ® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy. “Small cell lung cancer is one of the most aggressive malignancies, with a high unmet need for more effective therapies. 1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care,” said Jay Bradner, M.D., executive vice president, Research and Development, at Amgen. “We look forward to sharing these results with the scientific community and health authorities as we continue our efforts to bring IMDELLTRA to patients worldwide.” The safety profile for IMDELLTRA was consistent with its known profile. Detailed data from DeLLphi-304 will be presented at an upcoming medical congress. DeLLphi-304 is a global Phase 3 randomized controlled open-label clinical trial evaluating the efficacy and safety of IMDELLTRA as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy. 2 Patients were randomized to receive either IMDELLTRA or local SOC chemotherapy (topotecan in all countries except Japan; lurbinectedin in the U.S., Canada, Australia, Singapore, Korea; and amrubicin in Japan). 2,3 The primary outcome measure of the trial is OS. 2 About IMDELLTRA ® (tarlatamab-dlle) IMDELLTRA is a first-in-class immunotherapy engineered by Amgen researchers that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell. 4,5 DLL3 is a protein that is expressed on the surface of SCLC cells in ~85-96% of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target. 6,7 IMDELLTRA ® (tarlatamab-dlle) U.S. Indication IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). About Small Cell Lung Cancer (SCLC) SCLC is one of the most aggressive and devastating solid tumor malignancies, with a 5-10% five-year relative survival rate across all stages combined. 1 SCLC comprises about 15% of the more than 2.4 million patients diagnosed with lung cancer worldwide each year. 8-10 Despite initial high response rates to first-line platinum-based chemotherapy, most patients quickly relapse within months and require subsequent treatment options. 9 About Tarlatamab Clinical Trials Amgen’s robust tarlatamab development program includes the DeLLphi clinical trials, which evaluate tarlatamab as both a monotherapy and in combination regimens in earlier lines of SCLC. Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study investigating tarlatamab in combination with standard of care therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 trial comparing tarlatamab monotherapy with standard of care chemotherapy in second-line treatment of SCLC; DeLLphi-305, a randomized Phase 3 trial comparing tarlatamab in combination with durvalumab versus durvalumab alone as first-line maintenance treatment in ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 trial of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second line or later ES-SCLC; and DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC. 11 For more information, please visit www.tarlatamabclinicaltrials.com . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , YouTube and Threads . Please see IMDELLTRA ® full Prescribing Information , including BOXED WARNINGS. REFERENCES: SOURCE: Amgen

Phase 3Phase 2Clinical ResultImmunotherapyAccelerated Approval

100 Deals associated with Topotecan Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02168	Topotecan Hydrochloride	L01XX17	DB01030

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Solid tumor	Japan	Nippon Kayaku Co., Ltd.	20 Nov 2013
Recurrent Cervical Cancer	European Union	Pfizer Europe MA EEIG	09 Jun 2010
Recurrent Cervical Cancer	Iceland	Pfizer Europe MA EEIG	09 Jun 2010
Recurrent Cervical Cancer	Liechtenstein	Pfizer Europe MA EEIG	09 Jun 2010
Recurrent Cervical Cancer	Norway	Pfizer Europe MA EEIG	09 Jun 2010
Ovarian Epithelial Carcinoma	European Union	Teva Pharmaceuticals Europe BV	21 Sep 2009
Ovarian Epithelial Carcinoma	Iceland	Teva Pharmaceuticals Europe BV	21 Sep 2009
Ovarian Epithelial Carcinoma	Liechtenstein	Teva Pharmaceuticals Europe BV	21 Sep 2009
Ovarian Epithelial Carcinoma	Norway	Teva Pharmaceuticals Europe BV	21 Sep 2009
Recurrent Lung Small Cell Carcinoma	European Union	Sandoz Pharmaceuticals DD (Belarus)	12 Nov 1996
Recurrent Lung Small Cell Carcinoma	Iceland	Sandoz Pharmaceuticals DD (Belarus)	12 Nov 1996
Recurrent Lung Small Cell Carcinoma	Liechtenstein	Sandoz Pharmaceuticals DD (Belarus)	12 Nov 1996
Recurrent Lung Small Cell Carcinoma	Norway	Sandoz Pharmaceuticals DD (Belarus)	12 Nov 1996
Ovarian Cancer	United States	Sandoz, Inc.	28 May 1996
Small Cell Lung Cancer	United States	Sandoz, Inc.	28 May 1996
Uterine Cervical Cancer	United States	Sandoz, Inc.	28 May 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain metastases	Phase 3	United States	GSK Plc	01 Dec 2006
Brain metastases	Phase 3	Canada	GSK Plc	01 Dec 2006
Brain metastases	Phase 3	Hungary	GSK Plc	01 Dec 2006
Brain metastases	Phase 3	Poland	GSK Plc	01 Dec 2006
Brain metastases	Phase 3	Russia	GSK Plc	01 Dec 2006
Brain metastases	Phase 3	Slovakia	GSK Plc	01 Dec 2006
metastatic non-small cell lung cancer	Phase 3	United States	GSK Plc	01 Dec 2006
metastatic non-small cell lung cancer	Phase 3	Canada	GSK Plc	01 Dec 2006
metastatic non-small cell lung cancer	Phase 3	Hungary	GSK Plc	01 Dec 2006
metastatic non-small cell lung cancer	Phase 3	Poland	GSK Plc	01 Dec 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02312245 (CTgov)	Phase 2	Platinum-Resistant Fallopian Tube Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma	13	Paclitaxel+Bevacizumab (Arm A (Avatar-directed Paclitaxel))	fnfqzgyfrc = hsifuyoidq lrxhrgezek (pdawqsoklk, lzdkpauome - yxctrqlthu) View more	-	05 Dec 2024
				Gemcitabine Hydrochloride (Arm B (Avatar-directed Gemcitabine Hydrochloride))	fnfqzgyfrc = gbucsybubp lrxhrgezek (pdawqsoklk, raqlhvyefx - xgwtpqoede) View more
NCT04947501 (N9, ASCO2024) Manual	Early Phase 1	High Risk Neuroblastoma	15	cyclophosphamidehostopotecanopovincristineistifosfamidecarboplatinetoposide	fazmkhrfov(yvtgimscae) = vaduwdrjsr xhqodfkbvv (alpsklzlwp ) View more	Positive	24 May 2024
				cyclophosphamideplatopotecansidvincristineifosfamidecarboplatinetoposide	zsndmglddr(zagqtmafce) = tlhaafapnl adhkgvnoui (wapxeesmcr ) View more
NCT02308527 (ITCC-SIOPEN BEACON-Neuroblastoma, Pubmed) Manual	Phase 2	Neuroblastoma	160	Temozolomideirinotecantopotecantemozolomidebevacizumab	rsmcwxjefe(emcsqiwqeq) = zmbyckpacj pbjdcijzsh (okjravfzpq, 17 - 37)	Positive	08 Jan 2024
				temozolomideemozolirinotecantopotecan	rsmcwxjefe(emcsqiwqeq) = qpshgfztmo pbjdcijzsh (okjravfzpq, 10 - 28)
NCT00960739 (MIITOP, Pubmed \| Pediatr Blood Cancer)	Phase 2	Neuroblastoma recurrent	-	<sup>131</sup>I-metaiodobenzylguanidine + Topotecan	zolhwjqbbz(aabcujkvxi) = qrmdyobhfp bojdqvrtsi (lhffgryeqn, 6 - 32) View more	Positive	01 Nov 2023
ESMO2023	Not Applicable	Small Cell Lung Cancer Second line	-	Lurbinectedin	alttiwrocm(prqtksyral) = rsvgwcauzv ldxedvyizy (ajjkapmazd )	-	21 Oct 2023
				Topotecan with or without trilaciclib	alttiwrocm(prqtksyral) = fkpushjbaa ldxedvyizy (ajjkapmazd )
ARVO2023	Not Applicable	Retinoblastoma	3	topotecan (Ophthalmic artery chemosurgery (OAC))	ssxforjckp(ustvbcfeba) = lbfcgmqakc cxugbvrzpi (hctxixpedd ) View more	-	23 Apr 2023
				topotecan (Intravenous infusion (IV))	ssxforjckp(zquckwpktg) = ddfvtytqbj yejvzwcnrm (zpdxzxoqge ) View more
NCT01600573 (TOPAZ, Pubmed)	Phase 1/2	Recurrent ovarian cancer	-	Pazopanib	kwjpdzbvap(sfllsspshb) = ertqbydxgf dwnrrrfppz (uwaueujxrr )	Positive	31 Mar 2023
NCT00803062 (Gynecologic Oncology Group protocol 240, Pubmed)	Phase 3	Advanced Cervical Carcinoma First line	452	paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2	spmkkcpucd(bhyjojafrk) = skqmeyuxqa wthbycuszv (psjcskgzlc )	Negative	08 Mar 2023
				cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2	spmkkcpucd(bhyjojafrk) = sqbtdjhlog wthbycuszv (psjcskgzlc )
NeCTuR (IGCS2022)	Not Applicable	Recurrent Cervical Cancer Second line	-	Topotecan, paclitaxel, and bevacizumab (TPB)	zazdpnjjcg(plgxaeecap) = rbpvigdjqk jbxlnxuldb (bszmqzbisi ) View more	Positive	04 Dec 2022
				Chemotherapy without TPB	zazdpnjjcg(plgxaeecap) = vanpoexfym jbxlnxuldb (bszmqzbisi ) View more
NCT02487095 (ASCO2022) Manual	Phase 2	Neuroendocrine Tumors	15	Berzosertib + Topotecan	fhozvhsrdh(rucsflncui) = agioxnjiti hvjnzkrzls (yxduoeisbu )	Positive	02 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis